Evaluation of drug safety with multicenter real-world data

doi:10.19803/j.1672-8629.20240016

Abstract

Abstract: Objective To explore the progress, hot spots, and developments of research on drug safety evaluation based on multicenter real-world data. Methods PubMed, Web of Science, and Scopus were searched for literature on drug safety evaluation using multicenter real-world data. Firstly, bibliometrix was used for visual analysis of the time the included literature was published and the distribution of countries and journals. In addition, the frequency, co-occurrence, and diachronic changes of keywords were displayed. Information on the target diseases, intervention drugs, research safety outcomes, real-world data sources, multicenter data sharing was retrieved. Results A total of 405 publications in 2004-2023 were included in the analysis, and the number of publications increased year by year. Research focused on pharmacological interventions in neoplasms treatment, including targeted drugs, chemotherapeutic drugs, glucocorticoids, immunological agents, oral anticoagulants and antiplatelet drugs for circulatory disorders. The keyword co-occurrence analysis found 10 keyword clusters, the top two of which involved safety and atrial fibrillation. The most important source of data was the registry (217/405, 53.5%) in these studies. Currently, most research centers shared data within the country, so research data mostly came from more than 10 institutions (158/280, 56.4%). Data was shared across countries in Europe in this field. Conclusion There is increasing research on drug safety evaluation based on multicenter real-world data. The related research covers a wide range, such as neoplasms and circulatory system diseases. Multicenter data sharing between countries is increasing. Advances in information technology can facilitate inter-country RWD information exchange. The more commonly used real-world data is registry data and hospital database information. Building a global and multicenter data management platform and sharing real-world multi-source data will catch on.

Key words: drug safety, pharmacovigilance, real-world data, bibliometrics, Bibliometrix, multicenter

CLC Number:

R954
R994.11

WANG Chunnan, QIN Shiru, ZHANG Meng, SONG Haibo, LIU Junchang, LI Ge, SUN Feng. Evaluation of drug safety with multicenter real-world data[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 703-708.

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.zgywjj.com/EN/10.19803/j.1672-8629.20240016

https://www.zgywjj.com/EN/Y2024/V21/I6/703

References

[1] SHANG PH, LIU J, XIA YY, et al.A systematic review and qualitative analysis of the definition and scope of drug safety in China[J]. Chinese Journal of Health Policy(中国卫生政策研究), 2009, 2(6): 39-44.
[2] LAVERTU A, VORA B, GIACOMINI KM, et al.A new era in pharmacovigilance: toward real-world data and digital monitoring[J]. Clin Pharmacol Ther, 2021, 109(5): 1197-1202.
[3] MENG RG, ZHUO L, QIAO R, et al.Application values of real-world evidence in post-marketing surveillances and evaluation for drug safety[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(7): 624-627.
[4] SHI SY, LIU ZX, ZHAO HY, et al.Real-world evidence and randomized controlled trials: the initiation, implementation, progress interpretation and revelation of RCT DUPLICATE (part 2)[J]. Chinese Journal of Epidemiology(中华流行病学杂志), 2022, 43(11): 1835-1841.
[5] SHI SY, LIU ZX, ZHAO HY, et al.Real-world evidence and randomized controlled trials: the initiation, implementation, progress interpretation and revelation of RCT DUPLICATE (part 1)[J]. Chinese Journal of Epidemiology(中华流行病学杂志), 2022, 43(11): 1828-1834.
[6] Center For Drug Evaluation, National Medical Products Administration. Guidelines (Trial Implementation) for Real World Data Used to Generate Real World Evidence[EB/OL](2021-04-13)[2024-02-15]. https://www.cde.org.cn/main/news/viewInfoCommon/ 2a1c437ed54e7b838a7e86f4ac21c539.
[7] BASCH E, SCHRAG D.The evolving uses of“real-world”data[J]. JAMA, 2019, 321(14): 1359-1360.
[8] LI G, YANG ZR, ZHAO HY, et al.External control in studies using real-world data: current situation and exemplar[J]. China Food & Drug Administration Magazine(中国食品药品监管), 2021(11): 56-61.
[9] QIN XN, CHEN WS, SHAO H, et al.Application and research method of real world research in the medical field[J]. Progress in Pharmaceutical Sciences(药学进展), 2021, 45(7): 512-523.
[10] FLYNN R, PLUESCHKE K, QUINTEN C, et al.Marketing authorization applications made to the European medicines agency in 2018-2019: what was the contribution of real-world evidence?[J]. Clin Pharmacol Ther, 2022, 111(1): 90-97.
[11] Food and Drug Administration. Use of real-world evidence to support regulatory decision-making for medical devices: draft guidance for industry and Food and Drug Administration staff[EB/OL]. (2017-08-31)[2023-12-10]. https://www.fda.gov/media/99447/download.
[12] FDA. Framework for FDA’s real-world evidence program [EB/OL]. (2018-12-31)[2023-12-10]. https://www.fda.gov/media/120060/download.
[13] FDA. Use of Electronic Health Record Data in Clinical Investigations[EB/OL]. (2018-12-06)[2023-12-10]. https://www.fda.gov/media/119659/download.
[14] FDA. Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drug and Biological Products[EB/OL]. (2022-09-08)[2023-12-10]. https://www.fda.gov/media/124795/download.
[15] NMPA. Guiding principles of real-world evidence supporting drug development and evaluation (trial implementation) [EB/OL]. (2020-01-03)[2023-12-10]. https://www.nmpa.gov.cn/yaopin/ypggtg/ypqtgg/20200107151901190.html.
[16] NMPA. Technical guiding principles of real-world study supporting the development and evaluation of children’s drugs (trial implementation)[EB/OL] (2020-08-27)[2023-12-10]. https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20200901104448101.html.
[17] LI H, PAN YG, WANG L.Bibliometrix: a new bibliometrics analysis software[J]. Journal of Academic Library and Information Science(大学图书情报学刊), 2018, 36(4): 93-104.
[18] NMPA.Good Clinical Practice[EB/OL] (2020-04-23)[2023-12-10]. https://www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20200426162401243.html.
[19] HUISMAN MV, TEUTSCH C, LU S, et al.Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from phase III of the GLORIA-AF registry[J]. Clin Res Cardiol, 2022, 111(5): 548-559.
[20] LAKKIREDDY D, REDDY Y M, DI BIASE L, et al.Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: Results from a multicenter prospective registry[J]. Journal of the American College of Cardiology, 2014, 63(10): 982-988.
[21] LAKKIREDDY D, REDDY Y M, DI BIASE L, et al.Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: Results from a multicenter prospective registry[J]. Journal of the American College of Cardiology, 2012, 59(13): 1168-1174.
[22] LARSEN TB, SKJØTH F, NIELSEN PB, et al. Comparative effectiveness and safety of non-Vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study[J]. BMJ, 2016, 353: i3189.
[23] Society of Cancer Big Data and Real World Study of China Anti-Cancer Association. Chinese expert consensus on big data and real world study in cancer research (2022 edition)[J]. Chinese Journal of Oncology(中华肿瘤杂志), 2022(12): 1330-1343.
[24] BAUMFELD AE, REYNOLDS R, CAUBEL P, et al.Trial designs using real-world data: the changing landscape of the regulatory approval process[J]. Pharmacoepidemiol Drug Saf, 2020, 29(10): 1201-1212.
[25] SANTORO F, NúñEZ-GIL IJ, VITALE E, et al. Aspirin therapy on prophylactic anticoagulation for patients hospitalized with COVID-19: a propensity score-matched cohort analysis of the HOPE-COVID-19 Registry[J]. J Am Heart Assoc, 2022, 11(13).
[26] SANTORO F, NUñEZ-GIL IJ, VITALE E, et al. Antiplatelet therapy and outcome in COVID-19: the health outcome predictive evaluation registry[J]. Heart, 2022, 108(2): 130-136.
[27] ALRASHED A, CAHUSAC P, MOHZARI YA, et al.A comparison of three thromboprophylaxis regimens in critically ill COVID-19 patients: An analysis of real-world data[J]. Front Cardiovasc Med, 2022, 9: 978420.
[28] REDDY P K, PATIL S, KHOBRAGADE A, et al.Evaluation of the safety and efficacy of favipiravir in adult indian patients with mild-to-moderate COVID-19 in a real-world setting[J]. Int J Gen Med, 2022, 15: 4551-4563.
[29] ZHONG L, LI YS, XIONG L, et al.Small molecules in targeted cancer therapy: advances, challenges, and future perspectives[J]. Signal Transduction and Targeted Therapy, 2021, 6(1): 201.
[30] BEDARD PL, HYMAN DM, DAVIDS MS, et al.Small molecules, big impact: 20 years of targeted therapy in oncology[J]. Lancet, 2020, 395(10229): 1078-1088.
[31] Cancer Rehabilitation and Palliative Professional Committee of Shanghai Anti-Cancer Association, Cancer Drug Clinical Research Committee of Shanghai Anti-Cancer Association, Cancer Prevention and Clinical Research Committee of Chinese Aging Well Association. Shanghai expert consensus on whole-process management of antineoplastic-induced nausea and vomiting (2024 edition)[J]. China Oncology(中国癌症杂志), 2024, 34(1): 104-134.
[32] Chinese Ecoi, Western Medicine C.Expert consensus on the diagnosis and treatment of integrated Chinese and Western medicine for myelosuppression caused by antitumor drugs[J]. Chinese Clinical Oncology(临床肿瘤学杂志), 2021, 26(11): 1020-1027.
[33] HUANG CX, ZHANG S, HUANG DJ, et al.Current knavledge and management recommendations of atrial fibrillation: 2018[J]. Chinese Journal of Cardiac Pacing and Electrophysiology(中国心脏起搏与心电生理杂志), 2018, 32(4): 315-368.
[34] YANG J, TANG YD.Application of novel oral anticoagulants in cardiovascular diseases[J]. Molecular Cardiology of China(中国分子心脏病学杂志), 2021, 21(4): 4142-4146.
[35] FLEURENCE RL, BLAKE K, SHUREN J.The future of registries in the era of real-world evidence for medical devices[J]. JAMA Cardiol, 2019, 4(3): 197-198.
[36] PENBERTHY LT, RIVERA DR, LUND JL, et al.An overview of real-world data sources for oncology and considerations for research[J]. CA Cancer J Clin, 2022, 72(3): 287-300.
[37] WENG HF, ZHANG YF, LIU B.Cross-border health services and digitalization in Europe[J]. Chinese Health Resources(中国卫生资源), 2021, 24(6): 820-825.
[38] JIA YL, YAO MH, LIU YM, et al.Exploring the patterns of real-world data governance in the context of special healthcare policy[J]. Chinese Journal of Evidence-Based Medicine(中国循证医学杂志), 2021, 21(12): 1373-1380.
[39] JIN FF, YAO C, MA J, et al.Explore efficient and feasible clinical real world data collection mode in Hainan Boao Lecheng International Medical Tourism Pilot Zone[J]. China Food Drug Administration(中国食品药品监管), 2020(11): 21-31.